Cargando…

Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis

BACKGROUND: Preoperative treatment of anti-vascular endothelial growth factor (VEGF) agents is extensively used in proliferative diabetic retinopathy (PDR), but the molecular mechanism is not fully understood. The objective of this research is to observe change of protein profile induced by ranibizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Chen, Han, Changjing, Zhao, Minjie, Yu, Jingjing, Bai, Lin, Yao, Yuan, Gao, Shuaixin, Cao, Hui, Zheng, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844103/
https://www.ncbi.nlm.nih.gov/pubmed/29541006
http://dx.doi.org/10.1186/s12014-018-9187-z
_version_ 1783305197888471040
author Zou, Chen
Han, Changjing
Zhao, Minjie
Yu, Jingjing
Bai, Lin
Yao, Yuan
Gao, Shuaixin
Cao, Hui
Zheng, Zhi
author_facet Zou, Chen
Han, Changjing
Zhao, Minjie
Yu, Jingjing
Bai, Lin
Yao, Yuan
Gao, Shuaixin
Cao, Hui
Zheng, Zhi
author_sort Zou, Chen
collection PubMed
description BACKGROUND: Preoperative treatment of anti-vascular endothelial growth factor (VEGF) agents is extensively used in proliferative diabetic retinopathy (PDR), but the molecular mechanism is not fully understood. The objective of this research is to observe change of protein profile induced by ranibizumab (an anti-VEGF agent) in vitreous humor from PDR patients and reveal the effects of anti-VEGF treatment on PDR. METHODS: A proteomic method was used to identify differentially expressed proteins in vitreous humor. Untreated PDR patients were defined as PDR group, while those who treated with intravitreal injection of ranibizumab (IVR) were defined as IVR. Gene Ontology (GO) annotation and REACTOME pathways were obtained from DAVID Bioinformatics Resources. Intravitreal level of apolipoprotein C-I (APOC1), serpin peptidase inhibitor clade A member 5 (SERPINA5), tissue inhibitor of metalloproteinases (TIMP2), and keratin 1 (KRT1) were determined by enzyme-linked immuno sorbent assay (ELISA). RESULTS: 339 differentially expressed proteins were identified in response to IVR. The most notable GO annotation describes the altered proteins was “innate immune response”. The most notable REACTOME pathway was “platelet degranulation”. ELISA result showed increased level of APOC1, SERPINA5, KRT1 and a decreased level of TIMP2 in PDR group compared with IVR. CONCLUSIONS: In addition to decreasing VEGF level, ranibizumab is associated with change of human vitreous protein profile in patients with PDR, in which the differential proteins are involved in immune response, platelet degranulation, complement activation etc., suggesting that the effects of VEGF are involved in these signaling pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12014-018-9187-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5844103
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58441032018-03-14 Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis Zou, Chen Han, Changjing Zhao, Minjie Yu, Jingjing Bai, Lin Yao, Yuan Gao, Shuaixin Cao, Hui Zheng, Zhi Clin Proteomics Research BACKGROUND: Preoperative treatment of anti-vascular endothelial growth factor (VEGF) agents is extensively used in proliferative diabetic retinopathy (PDR), but the molecular mechanism is not fully understood. The objective of this research is to observe change of protein profile induced by ranibizumab (an anti-VEGF agent) in vitreous humor from PDR patients and reveal the effects of anti-VEGF treatment on PDR. METHODS: A proteomic method was used to identify differentially expressed proteins in vitreous humor. Untreated PDR patients were defined as PDR group, while those who treated with intravitreal injection of ranibizumab (IVR) were defined as IVR. Gene Ontology (GO) annotation and REACTOME pathways were obtained from DAVID Bioinformatics Resources. Intravitreal level of apolipoprotein C-I (APOC1), serpin peptidase inhibitor clade A member 5 (SERPINA5), tissue inhibitor of metalloproteinases (TIMP2), and keratin 1 (KRT1) were determined by enzyme-linked immuno sorbent assay (ELISA). RESULTS: 339 differentially expressed proteins were identified in response to IVR. The most notable GO annotation describes the altered proteins was “innate immune response”. The most notable REACTOME pathway was “platelet degranulation”. ELISA result showed increased level of APOC1, SERPINA5, KRT1 and a decreased level of TIMP2 in PDR group compared with IVR. CONCLUSIONS: In addition to decreasing VEGF level, ranibizumab is associated with change of human vitreous protein profile in patients with PDR, in which the differential proteins are involved in immune response, platelet degranulation, complement activation etc., suggesting that the effects of VEGF are involved in these signaling pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12014-018-9187-z) contains supplementary material, which is available to authorized users. BioMed Central 2018-03-09 /pmc/articles/PMC5844103/ /pubmed/29541006 http://dx.doi.org/10.1186/s12014-018-9187-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zou, Chen
Han, Changjing
Zhao, Minjie
Yu, Jingjing
Bai, Lin
Yao, Yuan
Gao, Shuaixin
Cao, Hui
Zheng, Zhi
Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
title Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
title_full Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
title_fullStr Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
title_full_unstemmed Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
title_short Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
title_sort change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844103/
https://www.ncbi.nlm.nih.gov/pubmed/29541006
http://dx.doi.org/10.1186/s12014-018-9187-z
work_keys_str_mv AT zouchen changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT hanchangjing changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT zhaominjie changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT yujingjing changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT bailin changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT yaoyuan changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT gaoshuaixin changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT caohui changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis
AT zhengzhi changeofranibizumabinducedhumanvitreousproteinprofileinpatientswithproliferativediabeticretinopathybasedonproteomicsanalysis